124 related articles for article (PubMed ID: 37100229)
1. Hepatocellular carcinoma in a large cohort of type 2 diabetes patients.
Giorda CB; Picariello R; Tartaglino B; Nada E; Costa G; Manti R; Monge L; Gnavi R
Diabetes Res Clin Pract; 2023 Jun; 200():110684. PubMed ID: 37100229
[TBL] [Abstract][Full Text] [Related]
2. Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin.
Donadon V; Balbi M; Casarin P; Vario A; Alberti A
World J Gastroenterol; 2008 Oct; 14(37):5695-700. PubMed ID: 18837086
[TBL] [Abstract][Full Text] [Related]
3. Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis.
Ganne-Carrié N; Chaffaut C; Bourcier V; Archambeaud I; Perarnau JM; Oberti F; Roulot D; Moreno C; Louvet A; Dao T; Moirand R; Goria O; Nguyen-Khac E; Carbonell N; Antonini T; Pol S; de Ledinghen V; Ozenne V; Henrion J; Péron JM; Tran A; Perlemuter G; Amiot X; Zarski JP; Beaugrand M; Chevret S;
J Hepatol; 2018 Dec; 69(6):1274-1283. PubMed ID: 30092234
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis.
N'Kontchou G; Paries J; Htar MT; Ganne-Carrie N; Costentin L; Grando-Lemaire V; Trinchet JC; Beaugrand M
Clin Gastroenterol Hepatol; 2006 Aug; 4(8):1062-8. PubMed ID: 16844421
[TBL] [Abstract][Full Text] [Related]
5. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
Tsai PC; Kuo HT; Hung CH; Tseng KC; Lai HC; Peng CY; Wang JH; Chen JJ; Lee PL; Chien RN; Yang CC; Lo GH; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Lin CY; Su WW; Chu CH; Chen CJ; Tung SY; Tai CM; Lin CW; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Yeh ML; Huang CF; Hsieh MH; Huang JF; Dai CY; Chung WL; Chen CY; Yu ML;
J Hepatol; 2023 Feb; 78(2):281-292. PubMed ID: 36208843
[TBL] [Abstract][Full Text] [Related]
6. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease.
Donadon V; Balbi M; Mas MD; Casarin P; Zanette G
Liver Int; 2010 May; 30(5):750-8. PubMed ID: 20331505
[TBL] [Abstract][Full Text] [Related]
7. Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma.
Donadon V; Balbi M; Valent F; Avogaro A
World J Gastroenterol; 2010 Jun; 16(24):3025-32. PubMed ID: 20572306
[TBL] [Abstract][Full Text] [Related]
8. Non-invasive risk scores do not reliably identify future cirrhosis or hepatocellular carcinoma in Type 2 diabetes: The Edinburgh type 2 diabetes study.
Grecian SM; McLachlan S; Fallowfield JA; Kearns PKA; Hayes PC; Guha NI; Morling JR; Glancy S; Williamson RM; Reynolds RM; Frier BM; Zammitt NN; Price JF; Strachan MWJ
Liver Int; 2020 Sep; 40(9):2252-2262. PubMed ID: 32638496
[TBL] [Abstract][Full Text] [Related]
9. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.
van der Meer AJ; Feld JJ; Hofer H; Almasio PL; Calvaruso V; Fernández-Rodríguez CM; Aleman S; Ganne-Carrié N; D'Ambrosio R; Pol S; Trapero-Marugan M; Maan R; Moreno-Otero R; Mallet V; Hultcrantz R; Weiland O; Rutter K; Di Marco V; Alonso S; Bruno S; Colombo M; de Knegt RJ; Veldt BJ; Hansen BE; Janssen HLA
J Hepatol; 2017 Mar; 66(3):485-493. PubMed ID: 27780714
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for hepatocellular carcinoma by age, sex, and liver disorder status: A prospective cohort study in Korea.
Yi SW; Choi JS; Yi JJ; Lee YH; Han KJ
Cancer; 2018 Jul; 124(13):2748-2757. PubMed ID: 29669170
[TBL] [Abstract][Full Text] [Related]
11. Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case-control study.
Kim G; Jang SY; Han E; Lee YH; Park SY; Nam CM; Kang ES
Int J Cancer; 2017 Feb; 140(4):798-806. PubMed ID: 27861855
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular carcinoma in cirrhosis: incidence and risk factors.
Fattovich G; Stroffolini T; Zagni I; Donato F
Gastroenterology; 2004 Nov; 127(5 Suppl 1):S35-50. PubMed ID: 15508101
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes of non-alcoholic fatty liver disease and the risk factors for mortality and hepatocellular carcinoma in a Japanese population.
Kogiso T; Sagawa T; Kodama K; Taniai M; Hashimoto E; Tokushige K
J Gastroenterol Hepatol; 2020 Sep; 35(9):1579-1589. PubMed ID: 31975453
[TBL] [Abstract][Full Text] [Related]
14. Alcohol and HCV chronic infection are risk cofactors of type 2 diabetes mellitus for hepatocellular carcinoma in Italy.
Balbi M; Donadon V; Ghersetti M; Grazioli S; Valentina GD; Gardenal R; Mas MD; Casarin P; Zanette G; Miranda C; Cimarosti P
Int J Environ Res Public Health; 2010 Apr; 7(4):1366-78. PubMed ID: 20617035
[TBL] [Abstract][Full Text] [Related]
15. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
16. Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status.
Audureau E; Carrat F; Layese R; Cagnot C; Asselah T; Guyader D; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Chazouillères O; Mallat A; Grangé JD; Attali P; d'Alteroche L; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Pol S; Nahon P;
J Hepatol; 2020 Dec; 73(6):1434-1445. PubMed ID: 32615276
[TBL] [Abstract][Full Text] [Related]
17. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan.
Chen TH; Chen CJ; Yen MF; Lu SN; Sun CA; Huang GT; Yang PM; Lee HS; Duffy SW
Int J Cancer; 2002 Mar; 98(2):257-61. PubMed ID: 11857416
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan.
Tateishi R; Matsumura T; Okanoue T; Shima T; Uchino K; Fujiwara N; Senokuchi T; Kon K; Sasako T; Taniai M; Kawaguchi T; Inoue H; Watada H; Kubota N; Shimano H; Kaneko S; Hashimoto E; Watanabe S; Shiota G; Ueki K; Kashiwabara K; Matsuyama Y; Tanaka H; Kasuga M; Araki E; Koike K;
J Gastroenterol; 2021 Mar; 56(3):261-273. PubMed ID: 33427937
[TBL] [Abstract][Full Text] [Related]
19. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease.
Kanwal F; Kramer JR; Mapakshi S; Natarajan Y; Chayanupatkul M; Richardson PA; Li L; Desiderio R; Thrift AP; Asch SM; Chu J; El-Serag HB
Gastroenterology; 2018 Dec; 155(6):1828-1837.e2. PubMed ID: 30144434
[TBL] [Abstract][Full Text] [Related]
20. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
